Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
January 10 2022 - 8:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
January 10, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share
repurchase programme
Bagsværd,
Denmark, 10 January 2022 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with
Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation
(EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme
of up to DKK 20 billion to be executed during a 12-month period beginning 3 February 2021.
Under the programme initiated 5 November 2021, Novo Nordisk
will repurchase B shares for an amount up to DKK 3.7 billion in the period from 11 November 2021 to 1 February 2022.
Since the announcement 22 December 2021, the following transactions
have been made:
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
2,909,544
|
2,126,697,543
|
3 January 2022
|
110,000
|
722.97
|
79,526,779
|
4 January 2022
|
110,000
|
690.91
|
75,999,885
|
5 January 2022
|
110,000
|
688.99
|
75,788,576
|
6 January 2022
|
110,000
|
669.84
|
73,682,907
|
7 January 2022
|
115,000
|
663.27
|
76,275,503
|
Accumulated under the programme
|
3,464,544
|
|
2,507,971,192
|
The details for each transaction made under the share repurchase programme
are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of
31,654,276 B shares of DKK 0.20 as treasury shares, corresponding to 1.4% of the share capital. The total amount of A and B shares
in the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK
20 billion during a 12- month period beginning 3 February 2021. As of 7 January 2022, Novo Nordisk has since 3 February 2021
repurchased a total of 32,900,725 B shares at an average share price of DKK 571.52 per B share equal to a transaction value of DKK
18,803,497,636.
Novo Nordisk is a leading global healthcare company, founded in 1923
and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and
rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170
countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media:
|
|
|
Mette Kruse Danielsen
|
+45 3079 3883
|
mkd@novonordisk.com
|
Michael Bachner (US)
|
+1 609 664 7308
|
mzyb@novonordisk.com
|
|
|
|
Investors:
|
|
|
Daniel Muusmann Bohsen
|
+45 3075 2175
|
dabo@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
David Heiberg Landsted
|
+45 3077 6915
|
dhel@novonordisk.com
|
Mark Joseph Root (US)
|
+1 848 213 3219
|
mjhr@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 01 / 2022
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: January 10, 2022
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Aug 2023 to Aug 2024